Article
Design, development, and evaluation of gene therapeutics specific to KSHV-associated diseases
5 Sept 2025
Abstract excerpt
-TK injection/GCV showed no detectable side effects. Our proof-of-concept studies highlight a promising strategy for targeting cancers driven by herpesviruses.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
